Epizyme, Inc. (EPZM) is a biotherapeutics company engaged in the commercialization of therapeutics for oncological disorders using novel epigenetic treatments. The pipeline candidates of the company include Tazemetostat for curing follicular lymphoma, R-CHOP for DLBCL, and PARP for solid tumors.
The price of EPZM stock during the regular trading on February 1, 2022, was $1.23. At last check in the pre-market, the stock gained by 8.94%.
EPZM: Events and Happenings
On February 1, 2022, EPZM’s employee bought 22,666,667 shares of the company’s stock at a price of $1.5 per share. On January 27, 2022, EPZM reported about the public pricing of its common stock shares of 56,666,667 shares at $1.50 per share price. The company had also granted the underwriters the acquisition of additional 8,500,000 common stock shares. The net proceeds expected by the company from the offering are approximately $85.0 million.
On January 10, 2022, EPZM updated about the preliminary results of the fourth quarter of 2021. The company estimated the revenue to be approximately $20.4 million while the earnings per share are estimated to beat by $0.52.
On December 12, 2021, EPZM’s Executive management presented the data of TAZVERIK at the 63rd American Society of Hematology’s Annual Meeting. On December 11, 2021, the company’s management presented the data of EZM0414 at the 63rd Annual Meeting of the American Society of Hematology.
On November 12, 2021, EPZM updated about the participation of its Executives at the Jefferies London Healthcare Conference on November 18, 2021.
EPZM: Key Financials
On November 9, 2021, EPZM announced its third-quarter 2021 financial results. The quarter ended on September 30, 2021. Some of the key updates are as follows.
Revenue
Total revenue in Q3 2021 was $5.2 million, compared to $3.6 million in Q3 2020. The company missed the revenue by $3.45 million.
Earnings/Loss per Share
EPS in Q3 2021 were $65.8 million, or $0.64 per share compared to $56.1 million or $0.55 per share in the same quarter of 2020. The company beat the EPS by $0.20 during the quarter.
Conclusion
EPZM stock’s performance is on a downward spiral by 81% from the past few months period. The stock looked well-positioned in the recent pre-market after the current insider transaction of shares by its employee. The financial experts have a strong consensus about the company’s earnings improvement.
